Catalyst Dossier · compiled by CeliA 🧫
ASTRAZENECA PLC (AZNCF)
Biotechnology · market cap $290.6B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-23 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
AstraZeneca PLC (AZNCF) is a large-cap global biopharmaceutical company with approximately 94,300 employees and a market capitalization of roughly $290.6 billion. The company operates an exceptionally broad pipeline spanning oncology, cardiovascular, respiratory, metabolic disease, and immunology, with multiple Phase 3 assets including Osimertinib (NSCLC), Camizestrant (breast cancer), Capivasertib (TNBC), and several other late-stage programs. Key near-term catalysts include high-importance Phase 3 readouts for Osimertinib and Camizestrant in early-to-mid 2027.
The catalyst path
- 2026-09-23 (est.)Phase 2 · Acalabrutinibimp 7/10
- 2026-09-26 (est.)Phase 2 · Zibotentan/Dapagliflozinimp 7/10
- 2026-09-30 (est.)Phase 3 · Oleclumabimp 9/10
- 2026-10-15 (est.)Phase 2 · Osimertinibimp 7/10
- 2026-11-15 (est.)Phase 2 · carboplatin AUC 2/paclitaxelimp 7/10
- 2026-12-15 (est.)Phase 2 · Tremelimumabimp 7/10
- 2026-12-31 (est.)Phase 3 · Androgen blockade + radiation therapyimp 9/10
- 2027-01-01 (est.)Phase 2 · Cediranibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| propranolol | Phase 3 | Migraine Without Aura |
| Iressa | Phase 2 | Skin Cancer |
| Quetiapine SR | Phase 3 | Anxiety Disorders |
| Ceftaroline fosamil | Phase 3 | Infections |
| Erlotinib 150/100 mg | Phase 3 | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer |
| Ticagrelor orodispersible tablets | Phase 3 | ST Elevation Myocardial Infarction |
| PwO | Phase 2 | Breast Cancer |
| CIN-107 2 mg dosing | Phase 2 | Primary Aldosteronism |
| MEDI4736 + Tremelimumab | Phase 2 | Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck |
| Paroxetine | Phase 3 | Generalized Anxiety Disorder |
| AZD2265 | Phase 3 | Metastatic Castration-resistant Prostate Cancer |
| MEDI3250 | Phase 3 | Healthy Japanese Children Age 2 Years Through 6 Years |
| Capivasertib | Phase 3 | Triple Negative Breast Neoplasms |
| Metformin IR | Phase 3 | Diabetes Mellitus, Type 2 |
| Formoterol (OT) | Phase 3 | Chronic Obstructive Pulmonary Disease |
| Tomudex | Phase 2 | Inoperable or Recurrent Rectal Cancer |
| fostamatinib | Phase 3 | Rheumatoid Arthritis |
| Osimertinib First-Line | Phase 2 | Non-Small Cell Lung Cancer |
| FG-4592 | Phase 3 | Anemia |
| Arimidex | Phase 2 | Breast Cancer |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AZNCF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.